India's pharmaceutical industry has experienced considerable change in the last 12 years, improving healthcare access, encouraging low-cost medications, and boosting independence in drug manufacturing. The Government reports that India has become the third-largest pharmaceutical producer globally by volume and is among the top suppliers of generic medicines worldwide, providing affordable healthcare options to more than 200 countries and regions. Policy measures like the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, the Promotion of Bulk Drug Parks Scheme, and assistance for medical device manufacturing have bolstered local production capabilities, decreased reliance on imports, and enhanced the resilience of pharmaceutical supply chains. The Government has broadened access to affordable medications via the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), where over 15,000 Janaushadhi Kendras are offering quality medicines at greatly reduced prices nationwide, aiding millions of individuals. The growth of the sector has been bolstered by increasing investments in research and development, biotechnology, vaccine production, and pharmaceutical infrastructure, allowing India to enhance its expertise in complex generics, biosimilars, and specialty drugs. India was crucial in providing medicines and vaccines worldwide during and after the COVID-19 pandemic, strengthening its status as the “Pharmacy of the World.” The pharmaceutical sector has played a crucial role in job creation, increasing exports, and making healthcare more affordable while backing the Atmanirbhar Bharat initiative. Ongoing focus on innovation, regulatory changes, local manufacturing, and healthcare accessibility is likely to boost India’s global competitiveness, bolster pharmaceutical exports, and aid long-term growth, positioning the sector as a crucial element of the nation's economic and healthcare development strategy. $PPLPHARMA $CIPLA $SUNPHARMA $GLENMARK